Skip to main content
. Author manuscript; available in PMC: 2010 Apr 1.
Published in final edited form as: Cancer Res. 2009 Mar 24;69(7):2801–2808. doi: 10.1158/0008-5472.CAN-08-4051

Figure 3. Effect of pharmacologic and genetic NOS-inhibition on peritumor lymphatic hyperplasia.

Figure 3

(A-C) Representative fluorescence images after FITC-Dextran lymphangiography. Animals received PBS or L-NMMA treatment starting on 7 days after T241-VEGF-C tumor implantation. Fourteen days after tumor implantation, lymphangiography was repeated and revealed that hyperplasic peritumor lymphatics in control animals (A) and attenuation in peritumor lymphatics hyperplasia in L-NMMA treated animals (B). (C) Quantification of the lymphatic vessel diameters after lymphangiography showed significantly reduced hyperplasia after 7 days of L-NMMA treatment. (D, E) Immunohistochemistry for LYVE-1 (D) and eNOS (E) shows that eNOS is expressed in peritumor lymphatics. Scale bars represent 100µm. (F) Rhodamine-Dextran lymphangiography revealed a significant reduction of peritumoral lymphatic hyperplasia in eNOS−/− mice implanted with T241-VEGF-C-GFP tumors compared to tumors implanted in wt mice. Normal ear lymphatics (control) had similar diameters. *P<0.05, **P<0.01, Student t test.